The heart transplant market is projected to grow significantly, reaching a value of approximately US$ 35,470.84 million by 2030, up from US$ 15,472.79 million in 2022.

This report outlines the current trends in the heart transplant sector, as well as the factors that are both promoting and inhibiting its growth.

A major driver of market expansion is the rising incidence of target diseases alongside an increasing elderly population. The aging demographic is particularly susceptible to cardiovascular diseases (CVDs), orthopedic issues, metabolic disorders, and neurological conditions. According to the World Health Organization (WHO), the global elderly population is expected to grow from around 1 billion in 2019 to approximately 2.1 billion by 2050. Despite this growth potential, the high costs associated with surgical procedures pose a significant barrier to the heart transplant market's advancement.

Companies within the heart transplant industry are actively pursuing strategic initiatives such as collaborations, expansions, agreements, partnerships, and the introduction of new products. These strategies are designed to boost sales, broaden geographic reach, and enhance their capabilities to serve a larger customer base. Below are some notable developments in the heart transplant market:

- In June 2021, Abbott Laboratories increased its manufacturing capacity and supply chain for the Medtronic HeartWare ventricular assist device (HVAD), a mechanical circulatory support (MCS) device. The company also initiated training and educational programs for healthcare professionals who plan to use HeartMate 3 heart pumps for their patients.

- In March 2023, BiVACOR Inc. received US$ 18 million in funding from Cormorant Asset Management and OneVentures through the OneVentures Healthcare Fund III. This financial support will enable the company to recruit key executives and advance its ongoing research and development, as well as early feasibility studies in human trials. BiVACOR aims to conduct its first human trials of the Total Artificial Heart by the end of 2023.

- In January 2022, BioVentrix acquired MateraCor Inc. along with its leading product. MateraCor specializes in using an injectable alginate-based hydrogel to halt and potentially reverse the progression of heart failure.

- In September 2021, SynCardia Systems LLC was acquired by Hunniwell Lake Ventures, a venture capital firm based in California. This acquisition has provided SynCardia with the operational and financial resources necessary for its continued growth and success in both domestic and international markets, allowing the company to innovate and explore new medical device applications.

The heart transplant market is categorized by surgery type into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplant segment dominated the market in 2022 and is expected to exhibit a higher compound annual growth rate (CAGR) of 11.1% during the forecast period. This method is the most commonly performed, where the recipient's heart is removed and replaced with a donor heart, which is then restored to its proper anatomical position. The donor heart must be preserved and transported within a 4-5 hour window, and the recipient is placed under general anesthesia and connected to a bypass machine to oxygenate the blood during the procedure.

In terms of heart type, the market is divided into donor live hearts and artificial hearts. The donor live heart segment held a larger market share in 2022, but the artificial heart segment is projected to grow at a higher CAGR of 11.6% during the forecast period. A living donor transplant involves removing a heart from a deceased individual and transplanting it into someone whose heart is failing. The demand for organ transplants has surged in recent years due to a shortage of hearts from deceased donors, leading to an increase in living organ donations. Most donors are declared dead after brain death tests, although they may still be on a ventilator, allowing their heart to continue beating. Historically, for the past 40 years, all transplanted hearts have come from living donors.

The heart transplant market is also segmented by end-user, which includes hospitals, cardiac centers, and other facilities. The hospitals segment accounted for a significant market share in 2022 and is expected to achieve a higher CAGR of 11.2% during the forecast period. Hospitals are comprehensive entities that offer a wide range of diagnostic and treatment services, often covered by insurance. They employ various healthcare professionals, including doctors and specialists, to provide high-quality care for all types of cardiovascular diseases, along with enhanced nursing services.

Key sources referenced in the preparation of this report include the United States Food and Drug Administration (USFDA), the Institute for Clinical and Economic Review (ICER), and the Centers for Disease Control and Prevention (CDC).